Validation of HDR brachytherapy doses in the treatment of keloid scars using the egs_brachy Monte Carlo application.

Objective. Radiotherapy is a well-known alternative in the treatment of keloid scars to reduce the recurrence of scars. The purpose of this study was to investigate the feasibility and accuracy of dose delivered from a high-dose-rate (HDR) afterloaders in keloid scar brachytherapy using Monte Carlo (MC) simulations and measurements.Approach. Treatment doses and central axis dose profiles were measured using radiophotoluminescence dosimeters and radiochromic films, respectively, with two HDR afterloaders, both using an Ir-192 source, in a phantom made of solid water and polycarbonate sheets. The nominal treatment dose calculated by the AAPM Task Group No. 43 (TG-43) dose model was set to 8.5 Gy at a distance of 0.5 cm laterally from the middle of the source line located in a plastic applicator simulating a 15 cm long surgically removed scar treatment with 30 equally spaced (0.5 cm) source positions. The dose profiles were measured at three different distances from the applicator and the absolute doses at four points at different distances. MC simulations were performed using the egs_brachy, which is based on EGSnrc code system.Main results. The measured and simulated dose profiles match well, especially at 10.0 mm (difference <1%) and 15.0 mm depths (difference <4%), and with a small dose difference at 5.0 mm depth (difference <4%). Point dose measurements agreed well in the dose maximum area (difference <7%) with the simulated dose profiles, although the largest difference near the edge of the profile was <30%. The dose differences between the TG-43 dose model and the MC simulation were small (differences <4%).Significance. Simulated and measured dose levels at a depth of 0.5 cm showed that the nominal treatment dose can be achieved with the utilized setup. The measurement results of the absolute dose agree well with the corresponding simulation results.

Saikkonen A ，Ojala J ，Sipilä P ，Boman E ，Keyriläinen J ... -  《-》

A generic TG-186 shielded applicator for commissioning model-based dose calculation algorithms for high-dose-rate (192) Ir brachytherapy.

A joint working group was created by the American Association of Physicists in Medicine (AAPM), the European Society for Radiotherapy and Oncology (ESTRO), and the Australasian Brachytherapy Group (ABG) with the charge, among others, to develop a set of well-defined test case plans and perform calculations and comparisons with model-based dose calculation algorithms (MBDCAs). Its main goal is to facilitate a smooth transition from the AAPM Task Group No. 43 (TG-43) dose calculation formalism, widely being used in clinical practice for brachytherapy, to the one proposed by Task Group No. 186 (TG-186) for MBDCAs. To do so, in this work a hypothetical, generic high-dose rate (HDR) 192 Ir shielded applicator has been designed and benchmarked. A generic HDR 192 Ir shielded applicator was designed based on three commercially available gynecological applicators as well as a virtual cubic water phantom that can be imported into any DICOM-RT compatible treatment planning system (TPS). The absorbed dose distribution around the applicator with the TG-186 192 Ir source located at one dwell position at its center was computed using two commercial TPSs incorporating MBDCAs (Oncentra® Brachy with Advanced Collapsed-cone Engine, ACE™, and BrachyVision ACUROS™) and state-of-the-art Monte Carlo (MC) codes, including ALGEBRA, BrachyDose, egs_brachy, Geant4, MCNP6, and Penelope2008. TPS-based volumetric dose distributions for the previously reported "source centered in water" and "source displaced" test cases, and the new "source centered in applicator" test case, were analyzed here using the MCNP6 dose distribution as a reference. Volumetric dose comparisons of TPS results against results for the other MC codes were also performed. Distributions of local and global dose difference ratios are reported. The local dose differences among MC codes are comparable to the statistical uncertainties of the reference datasets for the "source centered in water" and "source displaced" test cases and for the clinically relevant part of the unshielded volume in the "source centered in applicator" case. Larger local differences appear in the shielded volume or at large distances. Considering clinically relevant regions, global dose differences are smaller than the local ones. The most disadvantageous case for the MBDCAs is the one including the shielded applicator. In this case, ACUROS agrees with MC within [-4.2%, +4.2%] for the majority of voxels (95%) while presenting dose differences within [-0.12%, +0.12%] of the dose at a clinically relevant reference point. For ACE, 95% of the total volume presents differences with respect to MC in the range [-1.7%, +0.4%] of the dose at the reference point. The combination of the generic source and generic shielded applicator, together with the previously developed test cases and reference datasets (available in the Brachytherapy Source Registry), lay a solid foundation in supporting uniform commissioning procedures and direct comparisons among treatment planning systems for HDR 192 Ir brachytherapy.

Ma Y ，Vijande J ，Ballester F ，Tedgren ÅC ，Granero D ，Haworth A ，Mourtada F ，Fonseca GP ，Zourari K ，Papagiannis P ，Rivard MJ ，Siebert FA ，Sloboda RS ，Smith R ，Chamberland MJP ，Thomson RM ，Verhaegen F ，Beaulieu L ... -  《-》

Dosimetry of a sonolucent material for an ultrasound-compatible gynecologic high-dose-rate brachytherapy cylinder using Monte Carlo simulation and radiochromic film.

he purpose of this study was to study the dosimetric characterization of sonolucent material "TPX" to be used toward gynecologic high-dose-rate brachytherapy treatments using ultrasound-compatible cylinders in non-model-based dose calculation workflows. Monte Carlo simulations were performed using EGSnrc application egs_brachy in cylinders of polymethylpentene (TPX) plastic, water, and PMMA. Simulations were performed of five 192Ir sources placed longitudinally in ∼3.7 cm diameter, 5.0 cm length cylinders (matching physical cylinders used in film measurements). TPX and PMMA dose distributions and percentage depth dose curves were compared relative to water. Film measurements were performed to validate egs_brachy simulations. TPX and PMMA cylinders were placed in a water tank using 3D-printed supports to position film radially and touching the surface of the cylinders. The same five 192Ir dwell positions were delivered as simulated in egs_brachy. The egs_brachy and film percentage depth doses agreed within film uncertainties. The egs_brachy relative dose difference between TPX and water was (0.74 ± 0.09)% and between PMMA and water was (-0.79 ± 0.09)% over the dose scoring phantom. Dose differences for TPX and PMMA relative to water were less than ± 1% within 5 cm of the cylinder surface. In a solid sonolucent sheath of TPX, the dosimetric differences are comparable with PMMA and other applicator materials in clinical use. No additional uncertainty to dose calculation is introduced when treating through TPX cylinders compared with current applicator materials, and therefore, it is acceptable to perform gynecologic brachytherapy treatments with a sonolucent sheath inserted during radiation delivery.

Van Elburg DJ ，Roumeliotis M ，Morrison H ，Rodgers JR ，Fenster A ，Meyer T ... -  《-》

Dosimetric assessment of an air-filled balloon applicator in HDR vaginal cuff brachytherapy using the Monte Carlo method.

As an alternative to cylindrical applicators, air-inflated balloon applicators have been introduced into high-dose-rate (HDR) vaginal cuff brachytherapy to achieve sufficient dose to the vagina mucosa as well as to spare organs at risk, mainly the rectum and bladder. Commercial treatment planning systems which employ formulae in the AAPM Task Group No. 43 (TG 43) report do not take into account tissue inhomogeneity. Consequently, the low-density air in a balloon applicator induces different doses delivered to the mucosa from planned by these planning systems. In this study, we investigated the dosimetric effects of the air in a balloon applicator using the Monte Carlo (MC) method. The thirteen-catheter Capri™ applicator by Varian™ for vaginal cuff brachytherapy was modeled together with the Ir-192 radioactive source for the microSelectron™ Digital (HDR-V3) afterloader by Elekta™ using the MCNP MC code. The validity of charged particle equilibrium (CPE) with an air balloon present was evaluated by comparing the kerma and the absorbed dose at various distances from the applicator surface. By comparing MC results with and without air cavity present, dosimetric effects of the air cavity were studied. Clinical patient cases with optimized multiple Ir-192 source dwell positions were also explored. Four treatment plans by the Oncentra Brachy™ treatment planning system were re-calculated with MCNP. CPE fails in the vicinity of the air-water interface. One millimeter beyond the air-water boundary the kerma and the absorbed dose are equal (0.2% difference), regardless of air cavity dimensions or iridium source locations in the balloon. The air cavity results in dose increase, due to less photon absorption in the air than in water or solid materials. The extent of the increase depends on the diameter of the air balloon. The average increment is 3.8%, 4.5% and 5.3% for 3.0, 3.5, and 4.0 cm applicators, respectively. In patient cases, the dose to the mucosa is also increased with the air cavity present. The point dose difference between Oncentra Brachy and MC at 5 mm prescription depth is 8% at most and 5% on average. Except in the vicinity of the air-mucosa interface, the dosimetric difference is not significant enough to mandate tissue inhomogeneity correction in HDR treatment planning.

Jiang H ，Badkul R ，Pokhrel D 《Journal of Applied Clinical Medical Physics》

A generic high-dose rate (192)Ir brachytherapy source for evaluation of model-based dose calculations beyond the TG-43 formalism.

Ballester F ，Carlsson Tedgren Å ，Granero D ，Haworth A ，Mourtada F ，Fonseca GP ，Zourari K ，Papagiannis P ，Rivard MJ ，Siebert FA ，Sloboda RS ，Smith RL ，Thomson RM ，Verhaegen F ，Vijande J ，Ma Y ，Beaulieu L ... -  《-》